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Measurement of cell-free(cf) DNA in maternal blood has
been shown to provide effective prediction of fetal trisomy
21 and, to a lesser extent, of trisomies 18 and 13, both
in singleton and in twin pregnancy1,2. This has led to
clinical implementation of the test in several countries,
usually in women identified through prior screening by the
first-trimester combined test to have a high or moderate
risk for trisomy 21. In Belgium and The Netherlands,
however, cfDNA testing is being offered to all pregnant
women, as an alternative to the first-trimester combined
test, and the test is based on genome-wide (GW) analysis
rather than being confined to screening for the three major
trisomies. The rationale for such a policy is that GW
testing has the potential to diagnose clinically significant
rare autosomal trisomies (RATs) and rare additional fetal
segmental imbalances (SIs).
The results from the first year of GW-cfDNA testing
in The Netherlands (TRIDENT-2 study) included 56 818
women who underwent GW-cfDNA testing, from an
initial cohort of 73 239 women who had a cfDNA test;
in 207 (0.4%) of these women, the test was positive for
RATs (n = 101), SIs (n = 95) or complex abnormal pro-
files (n = 11)3. Among the 101 RATs, six were confirmed
but only one of these was associated with an abnormal
phenotype. Among the 95 SIs, 29 were confirmed but
the number with abnormality not discoverable through
ultrasound was not defined. In another seven cases con-
sistent with maternal malignancy or premalignancy, the
benefit of the discovery was not demonstrated. An abnor-
mal test result inevitably leads to anxiety and, in some
cases, to termination, as well as the need for both fetal and
maternal testing; however, even when the fetal karyotype
is found to be normal after a positive RAT result, uncer-
tainty persists as to whether there are true mosaicisms in
crucial fetal tissues and organs. When an invasive proce-
dure confirms a true fetal mosaicism after a positive RAT
result, it is impossible to predict clinical outcome and, in
case of confined placental mosaicism (CPM), except CPM
for trisomy 16, there is evidence that the incidence of
adverse pregnancy outcome in an unselected population
is not different from that in pregnancies with normal
karyotype at chorionic villus sampling (CVS)4. Therefore,
TRIDENT-2 shows that, at present, the benefits of screen-
ing for all genetic imbalances do not seem to outweigh
the potential harms and that clinical implementation,
even in a research setting, may be questionable ethically.
A study in Belgium, involving 3373 women, reported
that GW-cfDNA testing identified additional findings
beyond the common trisomies in 28 (0.8%) cases; these
included four sex-chromosome aneuploidies, six RATs
and one rare autosomal monosomy, none of which was
confirmed in the fetus or the neonate, as well as 17 large
or sub-microscopic SIs, of which three were confirmed
in amniocytes5. In all 28 cases, the clinical follow-up was
normal. Benn et al. reviewed the types of RAT identified
following CVS, as reported in 10 recently published
cfDNA studies, and found that the clinical outcome of
cases with cfDNA analysis positive for RATs mostly
involved the birth of an apparently normal baby (40%) or
a miscarriage/fetal loss (27%), for which screening tests
are not recommended6. There was a weak association
between RATs and pregnancy complications, such as
fetal growth restriction and fetal abnormalities, in the
tested population.
There are several points of concern that arise from
GW-cfDNA testing.
1) Increase in the screen-positive rate of a test that was
initially meant to reduce it, and increase in the rate
of invasive testing for conditions of unknown clinical
significance that remain of unknown significance even
after an invasive procedure.
2) There is uncertainty as to the clinical significance of a
heterogeneous set of chromosomal abnormalities and
how best to manage a positive result. Consequently,
no professional society currently recommends this
test7–11.
3) There is heterogeneity of home-brew massively
parallel shotgun sequencing protocols.
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4) There are ethical and legal challenges to overcome
regarding how best to counsel parents before they give
their informed consent, since accurate information
is lacking. In fact, women are already undergoing
GW-cfDNA screening without clear information
about its limitations and drawbacks, and clinical
decisions are already being made based on results
of uncertain clinical significance12–14. There are
also ethical concerns regarding increased voluntary
termination of pregnancy due to positive RAT results
even after a normal karyotype and normal ultrasound
scan.
5) The test violates World Health Organization screen-
ing principles15.
In conclusion, although research should always be
encouraged, the benefits vs harms of implementation
of GW-cfDNA screening must be weighed carefully.
Healthcare providers and grant-awarding bodies have
a responsibility to ensure that more robust data and
management strategies are available before endorsing
studies or strategies incorporating GW-cfDNA testing
into nationally reimbursed screening programs.
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